Brind.

Executive Order Accelerates Research into Psychedelic Therapies

Steady: 0 in the last 7 days Updated oct 5

The latest in this situation

  1. The EO accelerated psychedelic drug availability, prompting evaluation of ibogaine for OUD and PTSD.
  2. FDA and DEA are collaborating to accelerate investigational treatment pathways for psychedelic drugs.

How it started

21 reports, 12 independent, last reported Oct 5. The briefing below covers this first event.

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 12 independent outlets

An Executive Order was issued to accelerate the availability of psychedelic drugs, including ibogaine, for research purposes. The FDA is currently seeking public input on how to design early-phase clinical trials to evaluate the therapeutic uses of ibogaine for opioid use disorder (OUD) and post-traumatic stress disorder (PTSD). The FDA stated it has preliminary thinking on an initial, open-label trial design for these drug products.

From raps.org

Why it matters

Some supportBrind's analysis of the reports

The push follows a broader initiative launched by President Donald Trump's administration to expedite qualified psychedelic drug programs. The FDA is collaborating with the Drug Enforcement Administration on a pathway for some seriously ill patients to obtain investigational treatments. NIDA will fund research into ibogaine for OUD.

From raps.org, whtc.com

Who's involved

  • FDAThe FDA is evaluating and guiding the investigational drug pathways for psychedelic treatments.
  • Donald TrumpPresident Trump initiated the push to accelerate psychedelic drug programs through executive orders.
  • National Institute on Drug AbuseNIDA will fund research into ibogaine for OUD and PTSD.

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

How it developed

Newest first. Tap a step to see who reported it.
  1. The EO accelerated psychedelic drug availability, prompting evaluation of ibogaine for OUD and PTSD.1 source
  2. FDA and DEA are collaborating to accelerate investigational treatment pathways for psychedelic drugs.1 source
  3. Cohoba promotes the therapeutic use of mind-altering substances as an executive order pushes for expedited drug approvals.Sub-event
  4. Trump wanted FDA approval for psychedelic therapies. Heidi Overton advised on policy regarding the executive order, which led to team submissions to the Domestic Policy Council.Sub-event
  5. Executive order accelerates review of psychedelic treatments.1 source
  6. Executive Order accelerates psychedelic therapy research involving FDA, HHS, and the administration.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
8 more outlets ran the same wire story